Wolters Kluwer Health (EURONEXT: WKL) announced on Wednesday that it has launched AI Article Summary on its Ovid platform, enabling researchers to quickly extract insights from peer-reviewed literature. Currently in Beta across selected LWW proprietary journals, the tool uses generative artificial intelligence to deliver concise, trustworthy summaries, streamlining information gathering for healthcare professionals, researchers and students.
AI Article Summary helps users identify key points from lengthy research papers, addressing the challenge posed by the growing volume of daily published studies. The feature supports rapid knowledge sharing among colleagues and allows clinicians and researchers to stay current with the latest evidence. Summaries are structured consistently across journals, providing practical, actionable information that aligns with clinical decision-making.
Designed with research workflows in mind, Ovid's AI summarisation highlights critical findings and methodological insights without requiring users to leave the platform. Specialized prompt engineering ensures clinically and scientifically relevant information is extracted efficiently and reliably.
Wolters Kluwer is a global provider of information, software solutions, and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance; and ESG. The group reported 2024 revenues of EUR5.9bn, serving customers in over 180 countries with operations in more than 40 nations and a workforce of approximately 21,600. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement